XImmune has achieved the latest milestone according to the development plan with good results. LU Bio has therefore, as lead-investor, together with Dermagen AB and Sparbanksstiftelsen Skånes Riskkapitalstiftelse invested an additional SEK 4,4 million in the company. LU Bio now holds a 45,7% position in XImmune.